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 CURRENTOPINION Analgesic use in pregnancy and male
reproductive development
Pablo HurtadoAQ1 -Gonzalez and Rod T. Mitchell
Purpose of review
Male reproductive disorders are common and increasing in incidence in many countries. Environmental
factors (including pharmaceuticals) have been implicated in the development of these disorders. This review
aims to summarize the emerging epidemiological and experimental evidence for a potential role of in-utero
exposure to analgesics in the development of male reproductive disorders.
Recent findings
A number of epidemiological studies have demonstrated an association between in utero exposure to
analgesics and the development of cryptorchidism, although these findings are not consistent across all
studies. Where present, these associations primarily relate to exposure during the second trimester of
pregnancy. In vivo and in vitro experimental studies have demonstrated variable effects of exposure to
analgesics on Leydig cell function in the fetal testis of rodents, particularly in terms of testosterone
production. These effects frequently involve exposures that are in excess of those to which humans are
exposed. Investigation of the effects of analgesics on human fetal testis have also demonstrated effects on
Leydig cell function. Variation in species, model system, dosage and timing of exposure is likely to
contribute to differences in the findings between studies.
Summary
There is increasing evidence for analgesic effects on the developing testis that have the potential to impair
male reproductive function. However, the importance of these findings in relation to human-relevant
exposures and the risk of male reproductive disorders remain unclear.
Keywords
analgesics, male reproduction, NSAIDS, paracetamol, testis
INTRODUCTION
Development of the male reproductive system is
dependent on normal formation and function of
the testis during fetal life. Failure of normal develop-
ment may result in disorders that manifest in the
neonatal period (cryptorchidism and hypospadias),
or in adulthood (testicular cancer and poor semen
quality) [1,2&].
In humans, cryptorchidism occurs in 1–4.6% of
newborns, although it will often resolve naturally
leading to a prevalence of !1% at 1 year [3,4].
Cryptorchidism is associated with an increased risk
of testicular cancer, the commonest malignancy
amongst youngmen, which is believed to arise from
aberrant development of a population germ cells,
known as gonocytes, during fetal life [5]. Cryptorch-
idism is also associated with impaired spermato-
genesis resulting in a 30–60% risk of infertility in
adulthood [6]. Hypospadias is also a relatively com-
mon disorder occurring in approximately 0.2–0.6%
of male newborns [7]. The term Testicular
Dysgenesis Syndrome is frequently used to describe
the association of these disorders as a result of events
that occur during fetal life and their relationship
with deficient androgen production or action [8].
Indeed, a critical period from embryonic day
(e)15.5–e18.5, known as the ‘‘masculinization pro-
gramming window’’ (MPW), has been described
in fetal rats during which reduction in androgen
production or action leads to the subsequent devel-
opment of cryptorchidism and hypospadias [9]. A
similar period of sensitivity has been postulated to
AQ2
AQ3
MRC Centre for Reproductive Health, The University of Edinburgh, The
Queen’s Medical Research Institute, Edinburgh, Scotland, UK
Correspondence to Rod T. Mitchell, MRC Centre for Reproductive
Health, The University of Edinburgh, The Queen’s Medical Research
Institute, 47 Little France Crescent, Edinburgh EH16 4TJ, Scotland, UK.
Tel: +44 131 242 9288; fax: +44 131 242 6197;
e-mail: rod.mitchell@ed.ac.uk
Curr Opin Endocrinol Diabetes Obes 2017, 24:000–000
DOI:10.1097/MED.0000000000000338
1752-296X Copyright ! 2017 Wolters Kluwer Health, Inc. All rights reserved. www.co-endocrinology.com
REVIEW
CE: ; MED240309; Total nos of Pages: 9;
MED240309
occur in the first trimester in humans based in part
on the timing of divergence in anogenital distance
(AGD; an indicator of fetal androgen exposure)
between males and females [10].
These common male reproductive disorders
have increased in incidence over recent decades
indicating that in addition to genetic abnormalities,
environmental factors such as life style, diet, and
chemical (including pharmaceutical) exposures are
likely to play a role in their development [1,11&].
Recently, there has been an increasing literature on
the potential role of in utero exposure to analgesics,
including paracetamol and nonsteroidal anti-
inflammatory drugs (NSAIDS; e.g., ibuprofen or
aspirin), on male reproductive development. This
review will describe the emerging epidemiological
and experimental evidence in relation to analgesic
exposure and its potential effects on male
reproductive development.
ANALGESIC USE DURING PREGNANCY
Women are generally advised to avoid taking medi-
cations during pregnancy where possible. However,
despite this, the majority of women take one or
more analgesics such as paracetamol or NSAIDS,
at some point during pregnancy [12]. A Large Dan-
ish study (n¼46,500) reported analgesic use in 55%
of pregnant women [13], whereas a US study
(n¼10,533) reported 65% of pregnant women used
paracetamol (15% in combination with ibuprofen)
[12]. A smaller (n¼895) French study reported an
even higher frequency of analgesic use (81%) in
pregnant women [14]. Furthermore, the overall con-
sumption of analgesics has increased significantly in
the majority of European countries during the past
20 years [15&]. These analgesics are able to cross the
placenta and hence have the potential to cause
direct effects on the fetus [16–18]. It is not ethical
to test the effects of analgesics on pregnant women
directly and hence the evidence for associations
between analgesic use during pregnancy and the
development of male reproductive disorders derives
from a combination of epidemiological and exper-
imental studies conducted largely over the past
two decades.
EPIDEMIOLOGICAL STUDIES RELATING
TO ANALGESIC EXPOSURE AND
DEVELOPMENT OF MALE REPRODUCTIVE
DISORDERS
Association between analgesic use and
cryptorchidism
A significant association between the overall use of
mild analgesics during pregnancy and cryptorchid-
ism in the offspring has been demonstrated in
three studies with adjusted odds ratio (OR) of 1.93
(confidence interval [CI]: 1.03–3.62) [19], 2.12
(CI: 1.17–3.83) [20], and 2.30 (CI: 1.12–4.73) [21].
Another study did not demonstrate a significant
association (OR: 1.1; CI: 0.31–3.6) [14] (Table 1).
In two of the studies that demonstrated an associ-
ation this only reached statistical significance for
analgesic use during the second trimester with no
significant association during the first trimester
[20,21]. Interestingly, Kristensen et al. describe data
on two separate Scandinavian populations. The sig-
nificant associations were restricted to the Danish
cohort, whereas in the Finnish cohort, there were no
statistically significant associations [13]. Differences
between cohorts may relate to variations in meth-
odology, prevalence of cryptorchidism, or study
power. Duration of exposure may also be important
with a significant association between prolonged
(>2 weeks) use of mild analgesics during pregnancy
(includes first and second trimester) and cryptorch-
idism (OR: 2.47; CI: 1.02–5.96) [21]. Several of these
studies have also investigated the effects of specific
agents on the development of cryptorchidism.
Paracetamol exposure and risk of
cryptorchidism
Three studies investigating associations between
paracetamol use during pregnancy and cryptorchid-
ism have described adjusted OR>1.0; however,
these do not reach statistical significance (Table 1)
[13,19,20]. In one of these studies, exposure during
the second trimester was significantly associated
with cryptorchidism (OR: 1.89; CI: 1.01–3.51),
similar to their results for mild analgesics overall
[20], whilst this was not the case in the other studies
[13,21]. Timing of exposure is also likely to be
KEY POINTS
# Analgesics are used by the majority of women
during pregnancy
# Use of mild-analgesics during pregnancy has been
associated with an increased risk of cryptorchidism in
some studies
# Exposure to analgesics results in Leydig cell effects in a
number of experimental animal models of fetal
testis development
# The importance of human-relevant in-utero exposures to
analgesic in relation to male reproductive health
remains to be determined
Androgens
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Table 1. Association between analgesic exposure during pregnancy and male reproductive disorders
Analgesics Paracetamol Ibuprofen Aspirin
Study
period Cohort Publication
Gestational
period
adjusted OR
(95% CI)
adjusted OR
(95% CI)
adjusted OR
(95% CI)
adjusted OR
(95% CI)
Cryptorchidism 1996–2002 47,400 Jensen et al., 2010 [13] Pregnancyb n/a 1.33 (1.00–1.77) 0.88 (0.64–1.19) 1.18 (0.93–1.49)
First trimester n/a 0.94 (0.75–1.17) n/a n/a
Second trimester n/a 1.17 (0.89 –1.54) n/a n/a
2002–2006 3,184 Snijder et al., 2012
[20]
Pregnancy n/a n/a n/a n/a
First trimester 0.94 (0.36–2.46) 1.38 (0.52–3.64) n/a n/a
Second trimester 2.12 (1.17–3.83) 1.89 (1.01–3.51) 8.93 (1.84–43.24)a
1997–2001 491 Kristensen et al., 2011
[21] (Danish cohort)
Pregnancyb 1.43 (0.73–2.79) 1.337 (0.70–2.55) 1.82 (0.50–6.61) 2.22 (0.86–5.76)
First trimester 1.48 (0.66–3.34) 1.61 (0.66–3.90) n/a 5.60 (1.83–17.1)
Second trimester 2.30 (1.12–4.73) 1.97 (0.94–4.12) 4.59 (1.10–19.0) 3.76 (1.15–12.3)
1997–1999 1463 Kristensen et al., 2011
[21] (Finnish cohort)
Pregnancyb 0.74 (0.35–1.57) n/a n/a n/a
First trimester 0.77 (0.26–2.27) n/a n/a n/a
Second trimester 1.21 (0.53–2.76) n/a n/a n/a
2003–2006 903 Philippat et al., 2011
[14]
Pregnancyb 1.10 (0.31–3.6) n/a n/a n/a
1987–1990 6,699 Berkowitz & Lapinski.
1996 [19]
Pregnancy 1.93 (1.03–3.62) n/a n/a n/a
Hypospadias 2002–2006 3,184 Snijder et al., 2012
[20]
First trimester 2.05 (0.64–6.58) 2.24 (0.60–8.32) 1.65 (0.21–13.08)a
Second trimester 0.53 (0.12–2.34) 0.54 (0.12–2.41) n/a n/a
1997–2007 5851 Lind et al., 2013 [24] First trimester n/a 1.00 (0.80–1.10) 1.20 (1.00–1.30) 1.30 (0.90–1.70)
1982–1989 56,037 Correy et al., 1991
[25]
First trimester n/a n/a n/a 3.50 (1.40–8.80)
1959–1965 50,282 Slone et al., 1976 [23] First trimester n/a n/a n/a No association
1997–2004 14,915 Hernandez et al., 2012
[22]
First trimester n/a n/a No association
aApplies to ‘‘other’’ painkillers including NSAIDS.
bRefers to exposure during first and/or second trimester of pregnancy.
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important based on the evidence for an MPW in
rodents, postulated to occur between 8 and 14weeks
in humans [9]. Analysis of data from 8 to 14 weeks
demonstrated a hazard ratio (HR) of 1.14 (0.97–
1.34), which was significant for exposure>4 weeks
duration; OR: 1.38 (CI: 1.05–1.83) [13]. A second
study also demonstrated a significant association
OR: 2.78 (1.13–6.84) following prolonged (>2
weeks) exposure to paracetamol, similar to that
described for mild analgesics in general [21]. Again,
this association was restricted to the Danish and not
the Finnish cohort.
NSAID exposure and risk of cryptorchidism
The association between cryptorchidism and
exposure to NSAIDS, for example, ibuprofen and
aspirin, has also been investigated (Table 1)
[13,20,21]. No significant associations were demon-
strated for overall use of ibuprofen or aspirin during
pregnancy [13,21]. However, Kristensen et al. [21]
demonstrated a significant increase in cryptorchid-
ism following exposure to ibuprofen (OR: 4.59; CI:
1.10–19.0) and aspirin (OR: 3.76; CI: 1.15–12.3)
during the second trimester. A similar significant
association between exposure specifically during
the second trimester has also been demonstrated
in relation to ‘‘other’’ analgesics (i.e., analgesics
excluding paracetamol) [20].
These results may indicate the importance of
simultaneous use of more than one analgesic during
pregnancy. The use of$ 2 agentswas associatedwith
a significant increase in the risk of cryptorchidism
(OR: 7.72; CI: 2.09–28.6) in one study [21], whilst a
second study did not demonstrate a significant
association (OR: 1.07; CI: 0.82–1.40) [13].
Association between analgesic exposure and
risk of hypospadias
The majority of studies investigating analgesic use
during pregnancy and the incidence of hypospadias
have not shown significant associations (Table 1)
[20,22,23]. A study assessing analgesic exposure
from one month prior until 4 months after con-
ception showed a significantly increased risk of
hypospadias for ibuprofen (OR: 1.20; CI: 1.00–
1.30), whereas no association was reported for para-
cetamol or aspirin [24]. Another study reported a
significant association between the use of aspirin
and hypospadias (OR: 3.5; CI: 1.4–8.8) [25].
Analgesic exposure and anogenital distance
Cryptorchidism and hypospadias are associated
with a reduction in androgen production or action
during fetal life [9]. AGD has been shown to be a
reliable and robust measure of fetal androgen
exposure in rodents [13,20,21] and reduced AGD
has been associated with cryptorchidism and hypo-
spadias in humans [26,27]. It should be emphasized
that measurement of AGD in humans can be tech-
nically challenging and it is important that those
performing the measurements are sufficiently
skilled to avoid inter- and intra-observer bias. A
recent study investigated 1027 mother-child pairs,
recruited from 10 to 27 weeks of gestation, to deter-
mine the association between analgesic exposure in
mothers and AGD in the offspring at 3 months of
age [28&&]. No association was found between
exposure to paracetamol or NSAID and AGD; how-
ever, exposure to a combination of paracetamol and
‘‘other’’ analgesics (including NSAIDS) was associ-
ated with reduced AGDAS (ano-scrotal AGD; 32.3 vs.
36.2mm; P¼0.03) but not for AGDAP (ano-penile
AGD) which may relate to technical issues in con-
ducting thesemeasurements. In addition, this group
included relatively small numbers (n¼20). Further
investigation of the association between AGDand in
utero exposure to analgesics are warranted.
Taken together, the epidemiological evidence
indicates that there may be an association between
in utero exposure to analgesics, particularly during
the second trimester, and cryptorchidism. The evi-
dence for such an association with hypospadias is
less convincing. There are a number of limitations to
these studies relating to obtaining accurate infor-
mation regarding the dosage, timing, and duration
of analgesics exposure. This is particularly import-
ant for retrospective studies in which recall bias is a
potential limitation [19,20].
EXPERIMENTAL STUDIES RELATING
TO ANALGESIC EXPOSURE AND
DEVELOPMENT OF MALE REPRODUCTIVE
DISORDERS
Effect of analgesics on Leydig cell function in
the fetal testis
Testicular descent requires the action of two hor-
mones produced by Leydig cells, namely testoster-
one and Insulin-like growth factor 3 (Insl3) [29].
Several studies have investigated the effect of anal-
gesic exposure on Leydig cell function in the fetal
testis. This includes in vivo, ex-vivo and in vitro
model systems of paracetamol (Table 2) and NSAID
(Table 3) exposure using rodent and human tissues.
Analgesics and testosterone production
Testosterone production can be measured directly
(e.g., serum or intratesticular) or indirectly (e.g.,
Androgens
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AGD). Paracetamol exposure has been linked to a
reduction of fetal testicular testosterone production
in several studies [21,30&&,31] (Table 2). In-vivo
exposure of fetal rats to paracetamol (350mg/kg/
d) during the MPW significantly decreased AGD by
up to 10% in late fetal life [21,30&&], whereas another
study only demonstrated a significant effect on AGD
(15% reduction) at 10 weeks postnatally with no
effect at 4, 6, or 8 weeks [32&]. One of these studies
also described a significant reduction (40%) in intra-
testicular testosterone and in mRNA expression of
two key steroidogenic enzymes (CYP17a1 and
CYP11a1) indicating a potential mechanism for
the effect on steroidogenesis [30&&]. Another study
in rats did not demonstrate an effect of exposure
during this time-window on AGD at birth, although
there was an effect of exposure to a chemical ‘‘mix-
ture’’’’ that included paracetamol [33]. In vitro
Table 3. Leydig cell function following exposure to NSAIDS
Drug Species Model
Duration
(days) Dosea
Age (start of
treatment) Result Publication
Tesosterone Aspirin Rat In vivo 7 200 GD13 # (!60%)b Kristensen et al. 2011 [21]
In vitro 1 10mmol/L e14.5 # (!70%) Kristensen et al. 2011,2012 [21,31]
Human In vitro 3 100mmol/L 8–10 GW  " Mazaud-Guittot, 2013 [34]
In vitro 3 1mmol/L 10–12 GW $ Mazaud-Guittot et al. 2013 [34]
Indomethacin Rat In vivo 3 0.8 e15.5 $ Dean et al. 2013 [36]
In vitro 1 10mmol/L e14.5 # (!30%) Kristensen et al. 2012 [31]
Human In vitro 2 10mmol/L 8–12 GW " (!20%) Mazaud-Guittot et al. 2013 [34]
AGD Aspirin Rat In vivo 7 250 GD13 $ Kristensen et al. 2011 [21]
In vivo 3 150 GD11 # (!20%) Gupta and Goldman, 1986 [35]
Indomethacin In vivo 3 1 GD11 # (!20%) Gupta and Goldman, 1986 [35]
In vivo 3 0.8 e15.5 $ Dean et al. 2013 [36]
Insl3 Aspirin Human In vitro 3 10mmol/L 8–12 GW $ Mazaud-Guittot et al. 2013 [34]
Indomethacin In vitro 3 10mmol/L 8–12 GW $ Mazaud-Guittot et al. 2013 [34]
For significant effects ("/#), the result shown represents the minimum dose and shortest duration showing significance. For nonsignificant effects ($), the highest
dose and longest duration is shown. e, embryonic day; GD, gestational day; GW, gestational weeks.
aDoses are given by mg/kg/day unless otherwise stated.
bOnly significant after 3 h incubation (150mg/kg/d—no significant effect).
Table 2. Leydig cell function following exposure to paracetamol
Species Model
Duration
(days) Dosea
Age (start of
treatment) Result Publication
Testosterone Rat In vivo 7 350 GD13 $ Kristensen et al., 2011 [21]
In vivo 3 350 e13.5 # (!40%) van den Driesche et al., 2015 [30&&]
In vitro 2 1mmol/L e14.5 # (!50%) Kristensen et al., 2011 [21]
In vitro 2 1mmol/L e14.5 # (!25%) Kristensen et al., 2012 [31]
Human In vitro 1 10mmol/L 8–12 GW $ Mazaud-Guittot et al., 2013 [34]
Xenograft 7 60 14–20 GW # (!50%) van den Driesche et al., 2015 [30&&]
AGD Rat In vivo 7 150 GD13 # (!10%) Kristensen et al., 2011 [21]
In vivo 6 350 GD13 $ Axelstad et al., 2015 [33]
In vivo 3 350 e13.5 # (!10%) van den Driesche et al., 2015 [30&&]
Mouse In vivo 13 150 GD7 # (!15%) Holm et al., 2015 [32&]
INSL3 Rat In vivo 3 350 e13.5 $ van den Driesche et al., 2015 [30&&]
In vitro 3 100mmol/L e14.5 $ Kristensen et al., 2012 [31]
Human In vitro 3 10mmol/L 10–12 GW # (!40%) Mazaud-Guittot et al., 2013 [34]
For significant effects ("/#), the result shown represents the minimum dose and shortest duration showing significance. For nonsignificant effects ($), the highest
dose and longest duration is shown. e, embryonic day; GD, gestational day; GW, gestational weeks.
aDoses are given by mg/kg/day unless otherwise stated.
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studies have also demonstrated analgesic effects
during the MPW. Exposure of e14.5 rat fetal testis
to 1mmol/L paracetamol for 48h resulted in a 15–
50% reduction in testosterone with significant
reductions described across a range of doses (0.5–
10mmol/L) at 72h, whereas a similar approach using
culture of human fetal testis (8–12 weeks gestation)
did not demonstrate any effect on testosterone pro-
duction following exposure to 10mmol/L for 24, 48,
or 72h [34]. One study has investigated the effect of
exposure to a therapeutic regimen (60mg/kg/d) of
paracetamol (60mg/kg/d) on human fetal testis
(14–20 weeks gestation) xenografts. In this study
7 day exposure to paracetamol significantly reduced
seminal vesicle (androgen dependent organ) weight
(18% reduction) and serum testosterone (45%
reduction) in the castrate nudemice hosts compared
to vehicle controls, whilst a similar effect did not
occur following a shorter (1 day) exposure [30&&].
Differences between the results of the two studies
using human fetal testis may relate to the different
gestational ages or alternatively may reflect differ-
ences in model system.
Similar studies have been performed using
NSAIDs. In vivo studies have demonstrated a sig-
nificant reduction in AGD (!20% reduction) in
males exposed to aspirin (150mg/kg/day) or indo-
methacin (1mg/kg/day) from GD11 to 14 [35],
whereas no reduction in AGD was found in similar
studies involving exposure during the MPW in rats
[21,35], although in one of these studies testoster-
one production was reduced in the case of aspirin
[21] but not indomethacin [36]. However, in vitro
rat fetal testis studies have demonstrated a reduction
in testosterone production following 24h exposure
to aspirin (70% reduction; 10mmol/L) and indome-
thacin (30% reduction; 10mmol/L) from e14.5
[21,31]. These findings contrast with studies using
in vitro culture of human testis [34]. Exposure of
human fetal testis (8–12 GW) to indomethacin for
48h resulted in a significant increase in testosterone
(!20%; 10mmol/L). A similar increase was demon-
strated for aspirin exposure, although this was
restricted to 8–10GW, with no effect at 10–12GW
[34]. The reason for the discrepancy between the
effect of NSAID exposure on testosterone pro-
duction in the fetal rat and human testis is unclear
and may relate to the model systems or to genuine
species differences; however, this clearly illustrates
potential limitations of extrapolating effects in
rodent model systems directly into the human.
Analgesic exposure and Insl3 production
INSL3 is responsible for the first phase of testicular
descent and mutations in INSL3 gene may lead to
cryptorchidism in mice [37]. Paracetamol exposure
(350mg/kg/d) did not result in a change in Insl3
mRNA in rat fetal testis following in-utero exposure
from e13.5 to e16.5 [30&&]. This was also the case for
Insl3 measured in the media following in vitro
culture of rat fetal testis (e14.5) for 72h [31]. How-
ever, in human fetal (8–12GW) testis cultures para-
cetamol (10mmol/L; 72h) exposure resulted in a
significant reduction in Insl3 production, whilst
no effect was observed following exposure to the
same concentrations of aspirin or indomethacin
[34].
Overall, the experimental studies suggest that
exposure to analgesics can result in effects on Leydig
cells in the fetal testis which may have the potential
to result in male reproductive disorders. Whilst this
conclusion is supported by the results of studies
utilizing human fetal testis tissue there remain some
important questions relating to the dose and
duration of exposure and the degree of hormonal
suppression that might be required to induce male
reproductive disorders in humans. In addition, the
mechanism by which analgesics might affect Leydig
cell function requires further elucidation.
Effect of analgesics on prostaglandins
Prostaglandins have been proposed to play a role in
mediating the effects of paracetamol exposure on
Leydig cell function. Culture of e14.5 fetal rat testis
showed a significant decrease in prostaglandin D2
(PGD2) after 24h exposure to 1mmol/L paracetamol
[21]. However, there were no significant reductions
across a range of doses (1–100mmol/L) for 24, 48,
and 72h in a subsequent study by the same authors
[31]. For human fetal testis (7–12 weeks) in vitro
exposure to paracetamol (10mmol/L) for 72h did
not reduce prostaglandin D2 (PGD2) production,
but it did significantly reduce prostaglandin E2
(PGE2) [34].
For NSAIDS, the effect of exposure on prosta-
glandins appears to depend on the specific agent. A
dose dependent reduction in PGD2 after exposure to
aspirin was demonstrated in culture of e14.5 fetal rat
testis after 48 and 72h [21]; however, this was not
confirmed in a subsequent study, with nonsignifi-
cant reductions only occurring at 100mmol/L [31].
Similarly, for human fetal testis culture (7–12
weeks), no effect on PGD2 was observed following
aspirin (10mmol/L) exposure. However, similar to
results for paracetamol there was a significant
reduction in PGE2 following aspirin exposure [34].
For indomethacin, PGD2 was reduced following in
vivo and in vitro exposure of the fetal rat testis
during the MPW [21,36,38&&], which again was
not demonstrated in human fetal testis cultures
Androgens
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[34]. As with paracetamol and aspirin, exposure to
indomethacin did result in a significant reduction in
PGE2, albeit this was restricted to 7–10 weeks of
gestation. Taken together, the present data relating
to the effect of analgesics on prostaglandins appear
to indicate variable effects on prostaglandins
dependent, at least in part to the specific agents
and the model species.
Effect of analgesics on germ cell
development and fertility
Recent studies have begun to focus on the potential
for analgesics to affect germ cell development and
fertility including inter-generational effects
[38&&,39&&]. Dean et al. investigated the effects of
exposure of pregnant rats to 350mg/kg/day para-
cetamol or 0.8mg/kg/day indomethacin, during a
period of gestation that includes the MPW. Pups
exposed to indomethacin (male and female) showed
!50% decreased GC number and a decreased gona-
dal weight at e21.5 [38&&]. For females, this resulted
in reduced fertility, as indicated by a reduced num-
ber of pups per litter, whereas in males no effect on
fertility was seen. For paracetamol exposure, there
was a similar effect on females with significant
reduction in germ cell number, gonadal weight,
and pups per litter [38&&], with effects on fertility
also described for female mice exposed to paraceta-
mol in-utero [39&&]. However, for males, despite an
overall reduction in germ cell number and gonadal
weight at e21.5, there was no significant effect on
fertility [38&&]. Investigation of the reduced germ cell
numbers in males revealed premature loss of gon-
ocytes following exposure to both paracetamol and
indomethacin. The loss of this proliferative popu-
lation of germ cells is likely to result in the reduced
germ cell number; however, this is compensated for
by early puberty [38&&]. Another study involving
paracetamol (50mg/kg/d) exposure in mice (e7–
e13.5) showed no effect on male germ cells at
e13.5 or on germ cells or testicular weight in adult-
hood [32&]. The differences between the findings in
terms of the gonocyte population in fetal life may
relate to differences in species, paracetamol dose, or
timing of exposure.
Interestingly, recent studies have demonstrated
effects of analgesic exposure on the F2 generation
of rats exposed to paracetamol in utero. The F2
females exhibited a significant reduction in ovarian
weight and in primordial follicle number at pnd25.
Remarkably, this was seen independent of whether
the F1 parent was male or female, raising the intri-
guing possibility that this may be as a result of
epigenetic modification of the germline in both
sexes [38&&].
These recent rodent studies demonstrate that
analgesic exposure can affect germ cell development
in the fetal testis; however, these findings need to be
reproduced in human studies, including epidemio-
logical and experimental approaches.
CONCLUSION
Over the past 5 years, several studies have investigated
the potential effect of analgesic exposure to (para-
cetamol and NSAIDS) on the development of male
reproductive disorders. Epidemiological evidence
exists for associations between exposures to several
analgesics and the development of cryptorchidism.
Experimental studies in rodents have also demon-
strated effects during fetal life on Leydig cell function
(including testosterone production) and fertility.
Recent in vitro and ex vivo (xenograft) studies using
human fetal testicular tissue have lent support to the
concept that analgesic exposure may interfere with
Leydig cell function in the fetal testis. However, differ-
ences remain between the findings of these studies
that are likely to reflect variations in species, model
system, dosing schedule, and timing of exposure.
Further work is required to determine the potential
risk that analgesics may pose to human reproductive
health at human-relevant exposures. Whilst the cur-
rent evidence does not support a definitive answer to
this question, avoiding pain or pyrexia is important
for fetal health. With this in mind, a pragmatic
approach would be to use analgesics only when
necessary and for the shortest possible duration.
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